Oculis

📍 Lausanne, Switzerland🗓 Founded 2017👥 40 employees💰 Last funded Apr 2020
Biotechnology Research🌐 oculis.com
Website LinkedIn
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
3
Total investors
2
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
2
Iceland
1
Investor activity2016–2020 · investors recorded per year
201612017120201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Oculis?
Oculis has 3 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage.
When did Oculis last raise funding?
The most recent investment in Oculis recorded on gritt.io was in April 2020.
When was Oculis founded?
Oculis was founded in 2017.
What industry is Oculis in?
Oculis operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Oculis based?
Oculis is headquartered in Lausanne, Switzerland.